Business
KALY Conducts Cannabis Extraction Lab Site Survey For NOUV 100 Acer Hemp Farm
KALY Conducts Cannabis Extraction Lab Site Survey For NOUV 100 Acer Hemp Farm.
About this update from Kali Inc
[{"type":"text","content":"\nDALLAS, May 07, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced CEO Frederick Ferri is leading a site survey today of the cannabis extraction lab KALY is building in partnership with Nouveau (USOTC: NOUV) (“NOUV”) to facilitate extraction in conjunction with NOUV’s previously announced 100 acer hemp farm. NOUV currently operates a 25-greenhouse growing operation and in partnership with KALY plans to build an additional state-of-the-art greenhouse for the purpose of developing a proprietary cannabis cultivar. \n Patented Cannabis Extracts Targeting $170 In Million Pharmaceutical Treatments In the fourth quarter of last year, 2018, KALY acquired NCM Biotech (NCMB). NCMB is biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from a proprietary cannabinoid product platform in a broad range of disease areas. In four years of operations, the company has established a leading position in the development of plant-derived cannabinoid therapeutics through a proven drug discovery and patented development process. The resulting intellectual property portfolio and the established regulatory and manufacturing expertise have created a significant opportunity. KALY, through its subsidiary, NCMB has a deep pipeline of additional cannabinoid product candidates including four distinct compounds. KALY has completed the first stage of clinical development and testing for a Chronic Obstructive Pulmonary Disease (COPD) therapy and is currently conducting phase one development and trials for compounds targeting Cancer Pain Management, Type 2 Diabetes and Epilepsy. $170 Million Cannabis Therapeutics Market Opportunity   Chronic Obstructive Pulmonary Disease (COPD) - The market for COPD treatment is anticipated to reach $14 billion by 2025;  Type 2 Diabetes - The market for Type 2 Diabetes is expected to be a $64 billion market by 2026; Cancer Pain Management - The overall pain management treatment market is anticipated to reach $83 billion by 2024, and  Epilepsy - The market for epilepsy treatment is anticipated to reach $9 billion by 2022. $1 Million 2019 Revenue Target From Parallel Revenue Strategy KALY is not relying on its biopharmaceutical deve...